REPL · Replimune Group Inc.
AI read · Good for REPL
The AI's read
FDA granted accelerated approval to Replimune's Tudriqev for advanced cutaneous melanoma in combination with nivolumab. This gives Replimune an immediate commercial pathway after a bumpy regulatory run. The market barely moved, up about 3.8%, while REPL's RSI is very low at 15.64, suggesting buyers haven't fully stamped a new valuation. Approval is accelerated and hinges on confirmatory trials, so upside isn't free of risk. Our take leans bullish because approval unlocks commercialization and partners with a big oncology franchise. Position size should respect the remaining clinical risk and the market's consolidation regime.